Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Nihon Shokakibyo Gakkai Zasshi ; 116(4): 353-359, 2019.
Artigo em Japonês | MEDLINE | ID: mdl-30971673

RESUMO

A woman in her 60s visited our hospital due to elevation of ALP (1357U/L). The patient had been treated with lamivudine (LAM) in 2005, LAM+adefovir (ADV) in 2009, and ADV+entecavir in 2015 for chronic hepatitis B (CH-B). The ALP isozyme was predominantly bone type. Urinary ß-2 microglobulin (MG) and α-1MG increased to 49635µg/L and 64.1mg/L, respectively. Though no fractures were found during bone scintigraphy, the patient was diagnosed with Fanconi syndrome. However, 3 months after switching from ADV to tenofovir alafenamide (TAF), ALP decreased to 856U/L, and urinary ß-2MG and α-1MG decreased to 624µg/L and 6.0mg/L, respectively. Fanconi syndrome should be considered when an increase in ALP is observed in patients treated with ADV, and urinary ß-2MG and α-1MG assays are useful for establishing a diagnosis. Switching from ADV to TAF was an effective therapeutic option.


Assuntos
Adenina/análogos & derivados , Antivirais/uso terapêutico , Síndrome de Fanconi/tratamento farmacológico , Organofosfonatos/uso terapêutico , Adenina/uso terapêutico , Alanina , Fosfatase Alcalina/metabolismo , Biomarcadores/metabolismo , DNA Viral , Farmacorresistência Viral , Quimioterapia Combinada , Síndrome de Fanconi/diagnóstico , Síndrome de Fanconi/metabolismo , Feminino , Vírus da Hepatite B , Hepatite B Crônica/tratamento farmacológico , Humanos , Pessoa de Meia-Idade , Tenofovir/análogos & derivados , Tomografia Computadorizada por Raios X , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA